Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference


Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 40th Annual J.P. Morgan Healthcare Conference.

Mr. Lucchino's presentation will take place on January 13th at 10:30 a.m. ET and will be followed by a question-and-answer session immediately thereafter. A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequency's website, investors.frequencytx.com. A replay of the presentation will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function ? first in hearing loss and then in multiple sclerosis (MS) ? by developing therapeutics that activate a person's innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequency's hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.


These press releases may also interest you

at 13:35
A recent survey conducted by Vagaro, the leading salon, spa, and fitness software, highlights the significant presence of neurodivergent professionals in the beauty industry, with 50% of participants identifying as such. The research also showcases...

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...

at 13:30
Delmanor, a leading provider of retirement living communities, is thrilled to announce a groundbreaking partnership with Kite Mobility Inc., a pioneering force in electric mobility solutions. Together, they are revolutionizing retirement living by...

at 13:30
On Tuesday, Huntsman Corp. awarded 19 scholarships to Spring Independent School District (ISD) seniors pursuing four-year university degrees, or vocations in science, technology, engineering, or mathematics (STEM). During its annual Huntsman...

at 13:30
OneLayer, a leader in securing and orchestrating private LTE/5G networks for...

at 13:26
Class Technologies Inc., the global leader in virtual classrooms, today announced that it has been named to TIME's inaugural list of the World's Top EdTech Companies of 2024. This prestigious recognition acknowledges Class's impact on both education...



News published on and distributed by: